The best-evidenced thing about oats is not a superfood promise. It is a steady, modest fall in LDL cholesterol, seen across dozens of trials.
Oats are a rich source of beta-glucan, a viscous, soluble fibre recognised for its cholesterol-lowering properties (Ho et al., 2016). Because it is a fibre, human enzymes cannot digest it, so it carries on through the gut to the colon, where the resident microbes can ferment it. You can follow that journey in One meal, one axis.
The beta-glucan in oats is food for gut bacteria rather than for us. Most people carry gut bacteria from the Bacteroidetes group that are equipped to break beta-glucans down (Tamura et al., 2017, as cited in Cortijo-Alfonso et al., 2024). These are the bacteria that oats have been linked with in people.
Became more abundant when adults with mildly raised cholesterol ate 80 g of whole-grain oats a day, providing 3 g of beta-glucan, compared with rice. It lives in the gut’s mucus layer and is linked with a healthy gut barrier.
Also increased in the same oat trial. Roseburia ferments carbohydrates and produces butyrate. One species, Roseburia hominis, was among the bacteria most consistently linked with healthy diets in the ZOE PREDICT 1 study (Asnicar et al., 2021).
In the same trial, changes in Bifidobacterium, along with Akkermansia, Roseburia and Faecalibacterium prausnitzii, tracked the changes in blood lipids, suggesting that gut bacteria may contribute to the cholesterol-lowering effect of oats.
A large group of gut bacteria, many of which carry the molecular machinery to break down the mixed-linkage beta-glucans found in cereals such as oats and barley.
Dialister, Butyrivibrio and Paraprevotella also increased in the whole-grain oat trial. Not every oat study found changes, though. When older adults took 12 g a day of oat beta-glucan as an extract for six weeks, their gut bacteria did not change significantly, and the review describes the bacterial changes across oat and barley studies as highly varied. In several barley studies, who benefited depended partly on which bacteria people had to begin with (Cortijo-Alfonso et al., 2024).
Oat beta-glucan lowers LDL cholesterol. A meta-analysis of 58 randomised controlled trials with 3,974 participants found that a median dose of 3.5 g of oat beta-glucan a day lowered LDL cholesterol by 0.19 mmol/l (95% CI −0.23 to −0.14), with similar falls in non-HDL cholesterol and apolipoprotein B, compared with control diets (Ho et al., 2016). The effect is modest and consistent in direction, although the size of the effect varied considerably between trials for reasons the authors could not explain.
Effects on inflammation and the gut microbiota, in some groups. A systematic review of randomised trials of oats and barley found that five of nine studies measuring inflammatory markers reported significant reductions, mainly in longer studies of people at metabolic risk, such as those with high cholesterol. No anti-inflammatory benefit was seen in healthy people. Thirteen studies measured the gut microbiota and together suggest that oat and barley foods can change its composition, in some cases alongside metabolic improvements (Cortijo-Alfonso et al., 2024). The authors caution that the small number of trials, and differences in doses, products and participants, mean these conclusions should be interpreted with caution.
A route from oats to the gut-immune-brain axis. Oat fibre reaches the colon, can alter the microbial community there, and in people at metabolic risk may lower markers of inflammation (Cortijo-Alfonso et al., 2024). Each of those steps sits on the pathway that links diet to the brain, but none of the studies here measured cognitive outcomes, so any benefit for the ageing brain remains untested.
Asnicar, F., Berry, S. E., Valdes, A. M., Nguyen, L. H., Piccinno, G., Drew, D. A., Leeming, E., Gibson, R., Le Roy, C., Francis, L., Mazidi, M., Mompeo, O., Valles-Colomer, M., Tett, A., Beghini, F., Dubois, L., Bazzani, D., Thomas, A. M., Mirzayi, C., … Segata, N. (2021). Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nature Medicine, 27(2), 321–332. https://doi.org/10.1038/s41591-020-01183-8
Cortijo-Alfonso, M.-E., Romero, M.-P., Macià, A., Yuste, S., Moralejo, M., Rubió-Piqué, L., & Piñol-Felis, C. (2024). Effect of barley and oat consumption on immune system, inflammation and gut microbiota: A systematic review of randomized controlled trials. Current Nutrition Reports, 13(3). https://doi.org/10.1007/s13668-024-00543-x
Ho, H. V., Sievenpiper, J. L., Zurbau, A., Blanco Mejia, S., Jovanovski, E., Au-Yeung, F., Jenkins, A. L., & Vuksan, V. (2016). The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: A systematic review and meta-analysis of randomised-controlled trials. British Journal of Nutrition, 116(8), 1369–1382. https://doi.org/10.1017/S000711451600341X